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Abstract: Probiotics microorganisms exert their health-associated activities through some of the fol-
lowing general actions: competitive exclusion, enhancement of intestinal barrier function, production
of bacteriocins, improvement of altered microbiota, and modulation of the immune response. Among
them, Limosilactobacillus fermentum CECT5716 has become one of the most promising probiotics and it
has been described to possess potential beneficial effects on inflammatory processes and immunolog-
ical alterations. Different studies, preclinical and clinical trials, have evidenced its anti-inflammatory
and immunomodulatory properties and elucidated the precise mechanisms of action involved in its
beneficial effects. Therefore, the aim of this review is to provide an updated overview of the effect on
host health, mechanisms, and future therapeutic approaches.
Keywords: probiotic; Limosilactobacillus fermentum CECT5716; immunomodulation; dysbiosis; mech-
anisms of action; gastrointestinal diseases; microbiota
1. Introduction
The joint Food and Agriculture Organization (FAO) and World Health Organization
(WHO) defined probiotics as “live microorganisms which when consumed in adequate
amounts, confer a health effect on the host” [1]. Different characteristics are usually
required to consider a microorganism as a probiotic, including: (i) must be taxonomi-
cally characterized, (ii) able to survive to the human intestinal environmental conditions,
(iii) alive in sufficient numbers in the product at an efficacious dose throughout shelf life,
(iv) supported by at least one positive human clinical trial conducted according to generally
accepted scientific standards, and (v) safe for the intended use. Concerning the latter, most
of the probiotics are categorized by Food and Drug Administration (FDA) as Generally
Recognized as Safe (GRAS).
The microorganisms mostly considered as probiotics belong to the Lactobacillus and
Bifidobacterium genera, but also to other lactic acid bacteria, such as Lactococcus spp. and
Streptococcus thermophilus. Other probiotic strains include the genera Bacillus, Escherichia
(E. coli Nissle 1917), and Propionibacterium or yeasts like Saccharomyces boulardii.
Probiotics exert their health-associated activities through some of the following general
actions (Figure 1):
• Competitive exclusion of pathogenic microorganisms. This occurs when one species
of bacteria competes for receptor sites in the intestinal tract more actively than other
species [2].
• Enhancement of intestinal barrier function. The intestinal barrier function plays
an important role in the absorption of nutrients from food and, at the same time,
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prevents the access of potentially harmful bacteria to the human body [3]. When the
gut barrier is disrupted, food antigens and pathogenic microorganisms can develop
intestinal disorders, mainly associated with a local inflammatory response [4]. It
has been proposed that probiotics maintain the epithelial barrier function, through
increased expression of junction proteins or mucins, and promote intestinal epithelial
cell activation in response to bacterial infection [5,6].
• Production of bacteriocins. These are antimicrobial peptides that prevent the prolifera-
tion of selected pathogens [7].
• Improvement of the altered microbiota composition. In normal conditions, the gut
is colonized by a large number of microorganisms in balance, to provide energy
and nutrition, maintain the intestinal immune homeostasis and protect the intestinal
structure [8]. This balance is altered in many diseases, leading to a situation known as
dysbiosis [9].
• Modulation of the immune response. Immunomodulation can be achieved by several
mechanisms, including the modulation in the expression and/or production of anti-
and pro-inflammatory cytokines [10] or increased production of immunoglobulins
(Ig) [11].
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Figure 1. Mechanism of action of probiotics.
In addition to these general actions exerted by the probiotics, it has been reported that
other effects can also participate, which may be species- or even strain specific. However,
the exact underlying mechanisms of action for each probiotic are still unclear, and the
efficacy following their administration is quite different depend ng o the probiotic strain.
Therefore, a deeper understanding of the mechanisms involved in the beneficial effects
exerted by probiotics is especially relevant, and it should be considered that they must be
characterized for each specific probiotic.
The aim of this review is to provide an overview of the current applications of the pro-
biotic Limosilactobacillus fermentum CECT5716 and its potential use in different conditions,
based on its specific mechanisms reported in different preclinical and clinical studies.
2. Limosilactobacillus fermentum
Lactic acid bacteria (LAB) belong to the phylum Firmicutes, class Bacilli, order Lac-
tobacillales. They are considered to play important roles in food production, nutritional
supplementation, agriculture, as well as in veterinary and human medicine [12]. LAB are
Gram-positive bacteria, generally without catalase activity [13] that are able to produce
lactic acid as the main end-product after carbohydrate fermentation. Different genera
are considered in this LAB group: Aerococcus, Carnobacterium, Enterococcus, Lactobacillus,
Lactococcus, Leuconostoc, Oenococcus, Pediococcus, Streptococcus, Tetragenococcus, Vagococcus,
and Weissella [14]. LAB are present in different ecological niches, and many studies have
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established differences when considering their genetic and physiology [15]. The genus Lac-
tobacillus is certainly the most studied genus in the LAB group, and more than 240 species
have been reported to be included [16], which can be found at different localizations in the
human body, including the gastrointestinal tract, as well as the urinary and genital systems.
As commented above, this genus is considered one of the most important representative
groups of probiotics [17], and particularly, Lactobacillus fermentum has become one of the
most promising probiotics. In fact, it is used as a standard reference species in comparative
studies with other probiotics, due to their beneficial health properties [17].
Recently, whole genome studies have been performed, and the taxonomy of Lacto-
bacillaceae has been newly evaluated. Thus, the previous name, Lactobacillus fermentum, has
been changed by Limosilactobacillus fermentum [18].
L. fermentum is a species with many strains isolated from different environments,
including fermenting plant materials [19], dairy products [20], bread [21], naturally fer-
mented sausages [22], breast milk [23], saliva [24], and human feces [25]. Remarkably,
several L. fermentum strains have been described to possess promising beneficial effects
both in preclinical studies (in vitro and in vivo models) and in human trials, which, in fact,
have resulted in the development of different probiotic preparations for medical applica-
tion and food preservation processes [26]. Actually, it has been suggested a potential role
of L. fermentum in inflammatory-related diseases including intestinal inflammation [27],
respiratory tract infections [28] and hepatic injury [29] (Tables 1 and 2).
As expected, the mechanisms involved in the proposed beneficial effects reported for
these probiotics include the general mechanisms described above [30,31]. Among these,
the immunomodulatory properties have been proposed to have a key role in many strains
of L. fermentum, since they are able to interact with immune cells, like macrophages and
dendritic cells, as well as to regulate the synthesis and release of different cytokines [32,33].
In addition, L. fermentum strains have been proposed to exert bacteriostatic effects against
a variety of pathogenic bacteria and fungi, including Staphylococcus aureus [34], Candida
albicans [35], Helicobacter pylori [36], Campylobacter jejuni [37], and Aspergillus parasiticus [38],
derived from their ability to produce organic acids (primarily lactic and acetic acids) and/or
antimicrobial peptides [26,39]. Furthermore, it has been reported that some L. fermentum
strains possess a complete glutathione-associated system, including the synthesis, transport,
uptake, and redox cycling of this antioxidant peptide [40,41], thus providing protection
against oxidative stress (Tables 1 and 2).
Table 1. Effects of different L. fermentum strains in preclinical studies.




↑ IL-10 production THP-1 cell line [42]
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with the oxigenic radical
absorbance capacity (ORAC) assay




↑ Activity of glutathione
peroxidase (GSH-Px)
D-galactose-induced
aging KM mice [47]
Table symbols: ↓ Reduction and ↑ increase.
Table 2. Effects of different L. fermentum strains in clinical trails.
Strain/Origin Main Properties Physiological Conditions References
L. fermentum RC-14/female urogenital tract
−37% of improvement in vaginal flora
- ↑ lactobacilli population
- ↓ yeast levels
Healthy women [48]
L. fermentum VRI-003 PCC/unknown
(®Probiomics Ltd., Eveleigh,
NSW, Australia)
- ↑ lactobacilli population
- ↓ in the severity of gastrointestinal and
respiratory illness in sportive males.
Competitive athletes [49]
- ↓ Severity Scoring of Atopic Dermatitis
(SCORAD) index.
- ↑ the cases of mild atopic dermatitis.
Children with atopic dermatitis [50]
Combination of L. fermentum LF10 and
L. acidophilus La02/vaginal swabs of healthy
women or from direct brushing of gut
mucosa of healthy humans
↓ 72% of clinical recurrences vaginal
infections of vulvovaginal candidiasis
Women with recurrent
vulvovaginal candidiasis [51]
Combination of L. fermentum LF15 and
L. plantarum LP01/feces of healthy humans
or vaginal swabs of healthy female subjects
Reduction in the Nugent score and




L. fermentum ME-3/healthy Human
intestinal tract
- ↑ lactobacilli in feces
-Improvement the blood Total Antioxidative
Activity and Total Antioxidative Status
Healthy humans [53]
Combination of L. fermentum ME-3 and a
food supplement/healthy human
intestinal tract
-Improvement cardiovascular and diabetes
risk profile.
- ↓ total cholesterol
Clinically asymptomatic
humans [54]
Combination of L. fermentum ME-3, L.
paracasei 8700:2 and Bifidobacterium longum
46/healthy human intestinal tract and
human feces
- ↑ the blood Total Antioxidative Status
- ↓ oxidized/reduced glutathione ratio
Adult volunteers without
gastric symptoms [55]
Combination of L. fermentum LN99, L. gasseri
LN40, L. casei subsp. rhamnosus LN113 and
Pediococcus acidilactici LN23)/vaginal flora of
healthy women
-Vaginal colonization of lactobacilli
- ↓ recurrences of bacterial vaginosis and
vulvovaginal candidiasis




Table symbols: ↓ Reduction and ↑ increase.
However, of all strains identified from L. fermentum, L. fermentum CECT5716 is one of
the probiotics with more potential. Different studies have reported its possible beneficial
effects in different pathologies [57,58]. However, the precise mechanisms underlying re-
main unknown. Therefore, it is still necessary to conduct more investigations to identify
its mechanisms of action and possible interactions with the host. Here, we will sum-
marize and provide updated information on its effect on host health, mechanisms, and
therapeutic insights.
2.1. Limosilactobacillus fermentum CECT5716
L. fermentum CECT5716 is a probiotic strain initially isolated from the human breast
milk of healthy mothers, and for over 15 years, it has been included in nutrition sup-
plements and fermented milk products [23]. The application of whole-genome shotgun
strategies provided the identification of its genome using L. fermentum IFO 3956 as reference.
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Both strains are highly similar, with the exception of 16 protein encoding genes that are
not present in IFO 3965 [59]. Thus, the genome of L. fermentum CECT5716 is composed
of 2100449 bp and contains 1109 protein encoding genes, 54 tRNA encoding genes, and
20 rRNA encoding genes. It is a circular chromosome with a CG content of 51.49%, with
no plasmid, and includes putative enzymes with an important role in the metabolism of
purines (allantoinase, guanosine monophosphate (GMP) oxidoreductase, GMP synthase),
amino acids (serine-pyruvate transaminase, 3 glutamate synthases), lipids (acyltransferase),
and carbohydrates (mannose-6-phosphate isomerase) (GenBank/EMBL under accession
no. CP002033) [59].
2.1.1. Preclinical Studies
L. fermentum CECT5716 has been assayed in in vitro studies as well as in different
preclinical models such as experimental colitis, metabolic syndrome, lupus, and lactancy,
among others. Thus, it has shown potential benefits in health and disease, and the investiga-
tions have provided precious information about the mechanisms involved (Tables 3 and 4).
In addition, these studies have confirmed the safety of its intake, thus discarding any
toxicity on the host.
• In vitro studies
1. Epithelial cells.
a. CMT-93 cell line.
This cell line is derived from mouse rectum, and it is used as a model of intestinal
epithelial barrier to study the effects of different pharmacological agents on gut perme-
ability [60], intestinal inflammation [58] or colorectal cancer [61]. Therefore, CMT-93 cells
are a helpful tool to validate the effect or the mechanism of action of probiotics. Different
studies have been conducted using this cell line to evaluate the effectiveness of L. fermentum
CECT5716 administration. The incubation of lipopolysaccharide (LPS)-stimulated CMT-93
cells with L. fermentum CECT5716 has shown a significant reduction in the expression of
different proinflammatory cytokines, including Il-6 and Tnf-α, as well as an increase in
the expression of mucins, which can account to ameliorate the compromised gut barrier
integrity in an inflammatory environment [58]. Furthermore, L. fermentum CECT5716 and
CMT-93 co-culture revealed that the probiotic is able to restore the altered expression of
different miRNAs, including miRNA-150, miRNA-155, and miRNA-375 [58], described as
important regulators of intestinal inflammation, fine-tuning the immune system and the
mucosal barrier functions (Table 3).
b. Caco-2 cell line.
Caco-2 cell line was isolated from a human colorectal adenocarcinoma [62] and has
become one of the most widely used models for intestinal absorption, bioavailability, and
inflammatory studies [63,64]. Investigations performed in this cell line have supported the
potential of L. fermentum CECT5716 as a therapeutic tool to manage intestinal inflammation.
In fact, pretreatment of L. fermentum CECT5716 to stimulated Caco-2 cells has shown a
significant decrease in nitric oxide (NO), IL-8, and IL-1β in comparison with control cells.
Moreover, it was associated with a reduced phosphorylation of the Mitogen-activated
protein kinase (MAPK) p42/44 extracellular signal-regulated kinase (ERK) and p38 when
compared to stimulated cells without probiotic [50]. Surprisingly, Rodriguez-Nogales et al.
(2015) [65] demonstrated that L. fermentum CECT5716 viability was not necessary for its
immunomodulatory properties, reporting that this strain, live or dead, inhibited IL-8 pro-
duction by Caco-2 stimulated with IL-1β. This probiotic was also able to inhibit MAPK
activity showing a reduction in the phosphorylation of the MAPK p42/44 ERK and p38 [65]
(Table 3). These in vitro studies suggest that L. fermentum CECT5716 exerts immunomodu-
latory properties in epithelial intestinal cells, which might have a contributory role in the
anti-inflammatory effect at the intestinal level (Table 3).
2. Macrophages
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The immunomodulatory effects described on animal models and epithelial cells have
been also reported in different antigen-presenting cells.
a. Bone marrow-derived macrophages (BMDM).
BMDM are primary cells and in contrast to macrophage cell lines, they are mature
with biological function and properties of macrophages differentiated from monocytes.
BMDMs have been used for genetic screening (RNAi), drug screening, functional studies,
host–pathogen interaction studies, and many other areas of investigation [66–70]. Studies
performed using this cell model have shown that the probiotic L. fermentum CECT5716
downregulated the expression of pro-inflammatory mediators such as Tnf-a, Il-6, and iNos.
Moreover, it was also able to reduce TNF-α and IL-1β production on an inflammatory
phenotype of BMDM stimulated with LPS (LPS-stimulated BMDM cells) [71]. Recently, it
has also shown that the probiotic is able to restore the miRNA expression in LPS-stimulated
BMDM cells. Specifically, the probiotic was able to modulate the altered expression of
miRNA-150, miRNA-155, and miRNA-375. Theses miRNAs are associated with mucosal
leukocyte infiltration [72], induction of the macrophage activation and antigen presentation
by dendritic cells [73], and with the differentiation of goblet cells and the inflammatory
response of macrophages [74,75], respectively. Interestingly, all these miRNAs are up-
regulated in IBD patients [76] and the probiotic was able to restore their expression in
LPS-stimulated BMDM [58] (Table 3).
b. RAW 264.7 cells.
RAW 264.7 is a cell line derived from murine monocytes. RAW 264.7 cell line was estab-
lished from a tumor induced by the leukemia virus [77]. This cell line presents macrophage
properties [62], and it is used to study the anti-inflammatory effects of drugs and/or natural
extracts [78,79]. Consequently, the immunomodulatory effect of L. fermentum CECT5716
has been also evaluated in this macrophage cell line. The pretreatment of these cells with
L. fermentum CECT5716 resulted in a significant reduction in some mediators of inflam-
mation [80]. Exactly, L. fermentum CECT5716 reduced IL-1β and NO production when
compared with those cells untreated and LPS-stimulated [65]. Similarly, the probiotic, dead,
was also capable of reducing IL-1β and NO production when compared with those cells
untreated and stimulated with LPS [65] (Table 3).
c. Peripheral blood mononuclear cells.
Peripheral blood mononuclear cells (PBMCs) are extracted from whole blood. The
PBMCs are separated in a layer using Ficoll. This fraction of polymorphonuclear cells is
constituted by lymphocytes (T cells, B cells, and natural killer (NK) cells) and monocytes.
PBMCs are used as a powerful tool to screen compounds with immunomodulatory proper-
ties and determine their mechanism of action [81,82]. A study performed in 2010 evaluated
the potential activity of L. fermentum CECT5716 to modulate both human PBCMs activation
and cytokine profile. The results showed that the incubation of L. fermentum CECT5716
produced activation of both NK cells (CD8+ NK subset) and Treg cells (CD4+CD25+Foxp3+).
Moreover, the probiotic was able to induce different cytokines including Il-10, TNF-
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The effects shown by this probiotic strain in in vitro studies have been confirmed and 
supported by different preclinical studies.  
● Animal models. 
1. Models of experimental colitis. 
These models resemble human inflammatory bowel disease (IBD). It is a medical 
term that mainly includes two different clinical states, Crohn’s disease (CD) and ulcerative 
colitis (UC), and refers to specific chronic inflammatory states in the gastrointestinal tract. 
Its etiology is complex and not fully identified, involving interaction between genes, such 
as NOD2 and ATG16L1, and a number of functional abnormalities, like imbalance be-
tween pro-inflammatory, and anti-inflammatory T cell responses [58], impaired epithelial 
barrier function and gut microbiota dysbiosis [58]. Connecting the heritability and the en-
vironmental influence, unique microRNA (miRNA) expression profile signatures have 
been associated with IBD pathogenesis. In this regard, both endogenous gut miRNAs and 
exogenous miRNAs from diet could actively modulate microbial colonization and intes-
tinal immunity [84]. Thus, gut microbiota in IBD patients differs from healthy individuals, 
as it is characterized by a reduced diversity, increased abundance of Enterobacteriaceae and 
reduced abundance of Firmicutes and Bacteroidetes phyla [85]. As well as gut microbiota is 
key for the maintenance of gut homeostasis, it could also promote chronic inflammation 
and the development of IBD [86–88] (Table 4). 
In this regard, IBD patients display a modified balance between the T helper (Th)17/T 
regulatory (Treg) and the Th1, Th2, and Treg populations [89], having been proposed that 
a downregulation of Treg together with an increase in Th17 cells participate in the loss of 
tolerance for microbiota, that triggers inflammation [90]. Additionally, since the gut mi-
crobiota produces host-beneficial substances, the changes observed in the gut microbiota 
of IBD patients are associated with decreased levels of short-chain fatty acids (SCFAs), 
1β, IL-1β, IL-1
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Table 3. In vitro studies: mechanisms of action of L. fermentum CECT5716.
Experimental Models Mechanisms of Action Cell Model Reference
Epithelial cell lines
↓ Expression of pro-inflammatory profile (Il-6) and ↑ the mucins in
stimulated cells CMT-93 [58]
Restoration of miRNA-150, miRNA-155, and miRNA-375 expression
↓ NO, IL-8, and IL-1β in stimulated cells
Caco-2 [65]
↓MAPK p42/44 ERK and p38 in stimulated cells
Immune cells
↓ Pro-inflammatory mediators of stimulated cells (TNF-
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The effects shown by this probiotic strain in in vitro studies have been confirmed and
supported by different preclinical studies.
• Animal models.
1. Models of experimental colitis.
These models resemble human inflammatory bowel disease (IBD). It is a medical
term that mainly includes two different clinical states, Crohn’s disease (CD) and ulcerative
colitis (UC), and refers to specific chronic inflammatory states in the gastrointestinal tract.
Its etiology is complex and not fully identified, involving interaction between genes,
such as NOD2 and ATG16L1, and a number of functional abnormalities, like imbalance
between pro-inflammatory, and anti-inflammatory T cell responses [58], impaired epithelial
barrier function and gut microbiota dysbiosis [58]. Connecting the heritability and the
environmental influence, u ique microRNA (miRNA) expression profile signatures have
been associated with IBD pathogenesis. In this regard, both endogenous gut miRNAs and
exogenous miRNAs from diet could actively modul te microbi l colonization and intestinal
immunity [84]. Thus, gut microbiota in IBD patients differs from healthy individuals, as
it is characterized by a reduced diversity, increased abundance of Enterobacteriaceae and
reduced abundance of Firmicutes and Bacteroidetes phyla [85]. As well as gut microbiota is
key for the maintenance of gut homeostasis, it could also promote chronic inflammation
and the development of IBD [86–88] (Table 4).
In this regard, IBD patients display a modified balance between the T helper (Th)17/T
regulatory (Treg) and the Th1, Th2, and Treg populations [89], having been proposed that
a downregulation of Treg tog ther with an increase in Th17 cells participate in the loss
of tolerance for microbiota, that triggers inflammation [90]. Addition lly, since the gut
microbiota produces host-beneficial substances, the changes bserved in the gut microbiota
of IBD patients are associated with decreased levels of short-chain fatty acids (SCFAs),
which have anti-inflammatory properties and are one of the energy sources for colon
cells [91] (Table 4).
Despite the complexity of IBD, different experimental models are available, being the
dextran sulfate sodium (DSS), 2,4,6-trinitrobenze e s lfon acid (TNBS), or dinitrobenzene
sulfonic acid (DNBS), in rodents, the most used. T ey have been ve y useful for under-
standing the pathophysi logy of these conditions, as wel as for the development of new
therapeutic approaches and the elucidation of their mechanisms of action [92]. L. fermentum
CECT5716 has been ev luated in these models, obtaining promising results that suggest a
potential application against intesti al inflammation (Table 4).
a. TNBS-induced colitis in rats.
This model consists of the intra-rectally administration of the hapten TNBS diluted in
ethanol [93]. The intestinal inflammation initially results from ethanol-induced damage
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to intestinal epithelial cells, which increases permeability, microbial penetration into the
mucosa, and haptenization of host proteins by the TNBS, all leading to infiltration of neu-
trophils, macrophages, and Th1 T lymphocytes into the damaged mucosa [93]. Therefore,
this model is characterized by a dense colonic tissue infiltration by CD4 T cells and the
secretion of various potent pro-inflammatory cytokines [94]. Preventive studies performed
in TNBS-induced colitis in rats showed that oral administration of L. fermentum CECT5716
ameliorated the inflammatory response evidenced by downregulation of pro-inflammatory
mediators such as tumor necrosis factor (Tnf )-α, interleukin (Il)-6, and inducible nitric
oxide (iNos) [95,96]. The probiotic administration also reduced the histological damage
score, as well as the myeloperoxidase (MPO) activity [95,96], common marker of neutrophil
infiltration to evaluate the tissue damage in IBD [97]. Moreover, the probiotic supplemen-
tation was also able to increase the production of SCFAs in comparison with untreated
colitic rats. Additionally, L. fermentum CECT5716 pretreatment counteracted colonic glu-
tathione (GSH) depletion, which is considered a crucial event for colonic damage [98].
GSH is often recognized as a marker of oxidative stress and thus, as a consequence of its
antioxidant properties, scavenging of both oxygen and nitrogen reactive species [95]. The
preventive effects of L. fermentum CECT5716 may be due to both early immune stimulation
and immune regulatory properties, as well to its antioxidant abilities [95,96]. Additionally,
a curative study carried out with L. fermentum CECT5716 in the same TNBS model in rats
showed its effect in the late phase of colitis, being able to decrease leukotriene B4 (LTB4)
production, Il-6 expression, and Toll-like receptor (TLR)/MyD88 function [95]. Based on
these results, it can be stated that L. fermentum CECT5716 attenuates TNBS colitis, maybe
due to its antioxidant capacities, and effectively accelerates colitis recovery by enhancing
TLR function (Table 4).
These results confirmed that L. fermentum CECT5716 exhibits one the important fea-
tures of potential probiotic candidates, i.e., the capacity to modulate the immune response
of the host, which clearly contributes to its intestinal anti-inflammatory effect. However,
it is interesting to note that these beneficial effects are not exclusively dependent on the
probiotic viability, since both live and dead probiotic ameliorated the production of some of
the mediators involved in the colonic inflammation induced by TNBS in rats [65] (Table 4).
b. DNBS-induced colitis in mice.
This experimental model of colitis also employs rectal instillation of the mucosal sen-
sitizing agent DNBS. Similarly to TNBS, the intestinal inflammation is characterized by an
increased permeability, microbial penetration into the mucosa, infiltration of neutrophils,
macrophages, and Th1 T lymphocytes [93]. L. fermentum CECT5716 has also demonstrated
anti-inflammatory activity in this experimental model of mouse colitis. Its administration
prevented the DNBS-induced inflammation by ameliorating weight loss and the incidence
of diarrhea when compared with the untreated colitis group. Moreover, the treatment with
L. fermentum CECT5716 increased the survival rates due to a reduction in the inflammatory
process that it was manifested by the downregulation of several pro-inflammatory media-
tors such as Tnf -α, Il-1β, iNos, and metalloproteinase (Mmp)-9 as well as amelioration of
intestinal epithelial integrity showed by an increment of mucin (Muc)-3 and Occludin [58].
The probiotic was also capable of restoring the levels of miRNA-155 and miRNA-223 both
of them involved in the colitic process [99]. Moreover, the probiotic treatment ameliorated
gut microbiota composition increasing microbial diversity and the Firmicutes/Bacteroidetes
ratio, which is reduced in the DNBS-untreated group [58] (Table 4).
c. DSS-induced colitis in mice.
This model is based on the administration of DSS in drinking water resulting in
damage to the intestinal epithelium. This causes a dissemination of the luminal contents
into underlying tissue triggering an inflammatory response. It has also highlighted the
intestinal anti-inflammatory effect of L. fermentum CECT5716 in this model. In fact, it has
been confirmed that the preventative administration of L. fermentum CECT5716 exerted
intestinal anti-inflammatory effects and ameliorated dysbiosis. Thus, the treatment with
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L. fermentum CECT5716 reshaped the gut microbiota, increasing microbial diversity and
restoring the Firmicutes/Bacteroidetes ratio [27] (Table 4).
In summary, all the preclinical studies performed to evaluate the effect of L. fermentum
CECT5716 on IBD confirm its immunomodulatory activity and intestinal anti-inflammatory
properties. Among the mechanisms involved, it is interesting to highlight the positive
impact on the innate immune response, preserving the intestinal barrier integrity and
decreasing pro-inflammatory cytokines production, and on the adaptive immune response,
modulating the expression of Th1-, Th17-, and Treg-related cytokines. Moreover, it has
been demonstrated the ability of L. fermentum CECT5716 to restore intestinal microbiota
composition. Furthermore, it has been suggested that all these actions could be achieved at
a post-transcriptional level by modifying the expression of some miRNAs, which is altered
in these intestinal inflammatory conditions (Table 4).
• Metabolic syndrome.
Metabolic syndrome is a cluster of several disorders that include hypertension, hy-
perglycemia, and hyperlipidemia. Obesity is the common point of these alterations that
increase the risk of type-2 diabetes (T2D), cardiovascular disease, and cancer [100] (Table 4).
Moreover, obese patients have been reported a subclinical chronic inflammation, called
metaflammation [101] and associated with the secretion of pro-inflammatory mediators,
such as IL-6 and TNF-α. Thus, it promotes the recruitment of macrophages to adipose
tissues and contributes to the metabolic dysfunctions and obesity-related diseases in these
patients [101] (Table 4). This condition is developed as a consequence of an energy im-
balance due to an excessive energy intake and low expenditure, leading to an abnormal
accumulation of lipids in metabolic tissues, mainly adipose tissue and liver [102,103]. More-
over, many studies have pointed out the role of gut microbiota in the development of
metabolic syndrome [104]. It has been reported that an altered gut microbiota together
with an increased gut permeability promote bacterial endotoxins translocation into the
systemic circulation, which also contributes to the metaflammation [105]. In this sense,
several natural compounds such as probiotics have been assayed for the treatment of
metabolic syndrome [106,107] (Table 4). Among them, L. fermentum CECT5716 has demon-
strated to be a promising candidate to prevent these metabolic dysfunctions. Hypertension
is among the most prevalent risk factors for cardiovascular events such as stroke and
myocardial infarction. Up to present date, an ever-increasing number of studies have
shown a link between gut microbial signatures and hypertension [108,109]. Thus, a study
performed in spontaneously hypertensive rats (SHR) revealed the potential cardiovascular
effects of L. fermentum CECT5716 in genetic hypertension [110,111]. The study showed
that chronic treatment with L. fermentum CECT5716 prevented both gut dysbiosis (reduced
Firmicutes/Bacteroidetes ratio, increased butyrate-producing bacteria) and blood pressure
increase in SHR. In addition, the treatment restored the Th17/Treg balance in mesen-
teric lymph nodes, and normalized endotoxemia, as well as prevented the impairment of
endothelium-dependent relaxation to acetylcholine, as a result of reduced nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase-driven reactive oxygen species (ROS)
production. The probiotic was also able to prevent the vascular oxidative stress and en-
dothelial dysfunction mediated by the vascular LPS/TLR4 pathway [110,111] (Table 4).
Besides, it has been demonstrated that a synbiotic composed of L. fermentum CECT5716
and fructooligosaccharides prevented the development of liver steatosis and inflammatory
status in rats fed a high fructose diet. These effects were associated with changes in the
microbiota, restoring dysbiosis occurred in non-treated rats. The synbiotic also ameliorated
the glucidic profile by reducing the plasma levels of glucose and insulin, thus improving
homeostasis model assessment of insulin resistance (HOMA-IR) index, which is used to
determine the severity of insulin resistance and prevented the hypertriglyceridemia and
hyperleptinemia that occurred in rats fed the high fructose diet [112] (Table 4). These
findings reveal that this probiotic might be clinically useful in cardiovascular conditions,
particularly considering that high fructose intake has been related to metabolic syndrome
in humans. Supporting this, it has also been shown that L. fermentum CECT5716 prevents
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vascular oxidative stress and gut dysbiosis in rats with hypertension induced by chronic
NO blockade [113] (Table 4). In this study, the authors showed that the chronic L. fermen-
tum CECT5716 treatment reduced early events involved in atherosclerosis development,
such as vascular oxidative stress and pro-inflammatory status, as a result of prevention
of gut dysbiosis and immune changes in mesenteric lymph nodes, but not hypertension,
confirming the critical role of NO in the antihypertensive effects of L. fermentum CECT5716
in genetic hypertension [113] (Table 4).
Recently, L. fermentum CECT5716 has been evaluated in a model of high-fat diet (HFD)-
induced obesity in mice [114] (Table 4). This is very interesting since obesity is one of
the main features of metabolic syndrome. The treatment with L. fermentum CECT5716
to HFD-fed mice improved HFD-induced obesity, reducing body weight gain, which
was associated with an amelioration of glucose and lipid metabolism. The treatment did
not significantly modify energy intake, thus discarding any anorexigenic effect, but it
showed anti-inflammatory and immunomodulatory properties, as seen before in different
experimental models of intestinal inflammation [27,65] (Table 4). Indeed, L. fermentum
downregulated the expression of pro-inflammatory mediators in HFD-fed mice as well as
upregulated the expression of key transcription factors that control adiponectin such as
Ppar-α [115]. As in human obesity, this was associated with an improvement in glucose and
lipid metabolism, most probably derived from the amelioration of the obesity-associated
insulin resistance, as shown by the impact of the probiotic treatment on HOMA-IR values.
Furthermore, L. fermentum CECT5716 treatment ameliorated leptin resistance in liver and
adipose tissue as well as restored adiponectin expression in fat contents, which has been
previously reported for other probiotics, like different strains of L. plantarum [116,117].
Obesity-associated insulin resistance is also characterized by impairment of intracellular
glucose uptake that is mediated by the insulin-dependent receptor GLUT-4 [103], whose
expression is reduced when insulin resistance appears [118]. L. fermentum CECT5716 also
improved insulin resistance, which was associated with an increased expression of Glut-4,
ameliorating glycemic levels and glucose utilization by target tissues [119]. As commented
before, the obesity-associated inflammatory state is closely related to the development
of cardiovascular disease and endothelial dysfunction, in part, mediated by leptin [120]
(Table 4). Interestingly, L. fermentum CECT5716 treatment reduced vascular expression
of the pro-inflammatory cytokines Tnf-α and Il-1β in obese mice, as well as inhibited
the increased NADPH activity in the aortic tissue. This suggests a reduction in ROS
production and a higher NO bioavailability, which could promote the restoration of the
impaired endothelium-dependent relaxation to acetylcholine [114]. It is well described
that the gut plays an important role in the pathogenesis of obesity. In fact, there is a
defect in the intestinal barrier function that leads to increased gut permeability [121]
(Table 4). Therefore, bacterial components, like LPS, could reach systemic circulation and
provoke metabolic endotoxemia [122]. It has been confirmed these observations, since
obese mice displayed reduced expression of the colonic markers of epithelial integrity
as well as increased LPS plasma levels and upregulated expression of Tlr-4 in liver, fat,
and aorta [114]. Importantly, L. fermentum CECT5716 significantly increased the colonic
expression of the different markers involved in gut integrity in obese mice, thus restoring
the intestinal barrier function and preventing bacterial components translocation, since
it reduced LPS plasma levels and downregulated Tlr-4 expression [114]. In addition, it is
well established that gut microbiota composition is altered in obesity [123], consisting of
an enrichment in Firmicutes as well as a reduction in Bacteroidetes, both in humans [124]
and mice [125]. Increased Firmicutes/Bacteriodetes ratio has been associated with a more
efficient hydrolysis of non-digestible polysaccharides in the intestinal lumen, so obese
individuals extract more calories and fat from food than lean ones [126]. It has also been
demonstrated that L. fermentum CECT5716 treatment was able to modulate gut microbiota
composition, restoring the main bacteria phyla to the normal values observed in control
diet-fed mice [114]. This amelioration of obesity-associated dysbiosis could be associated
with the reduction in energy assimilation and potentially contribute to the beneficial effects
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observed [114]. Collectively, the probiotic was able to exert anti-obesity effects, maybe
related to its anti-inflammatory properties and amelioration of endothelial dysfunction
and gut dysbiosis [114]. This study, for the first time, shows the ability of this probiotic
to ameliorate experimental obesity through microbiome modulation, affecting different
bacteria that have been reported to play a key role in the pathogenesis of obesity [114]
(Table 4).
Taking into account all results on preclinical studies in metabolic syndrome, this pro-
biotic represents a very interesting approach on the prevention and therapy of metabolic
dysfunctions as well as they indicate a potential use of L. fermentum CECT5716 in clini-
cal practice.
• Systemic Lupus Erythematosus.
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease associated with
an increased risk of renal and cardiovascular disease development. SLE is characterized
by an alteration of the immune system, in which abnormally functioning B lymphocytes
promote an exacerbated production of autoantibodies that trigger the formation and
deposition of immune complexes, which in turn damage many organs and tissues [127].
The etiopathogenesis is still not fully understood, however, it is widely recognized that
SLE is the consequence of the effects of environmental factors in genetically predisposed
individuals, leading to the disruption of self-tolerance and to the activation/increase in
innate immune cells and autoreactive lymphocytes [128]. Although the mechanism of
the disease involves both genetic and environmental factors, it has been found that the
microbiota is also a key player [129]. The altered gut microbiota composition in SLE
patients is associated with an imbalance in the proportions of Th17 and Treg cells [130].
Considering all these facts, the use of probiotics with immunomodulatory properties is
widely justified for the treatment of this disease. In this scenario, it has been reported
that L. fermentum CECT5716 exerted beneficial effects in an experimental model of SLE in
mice, by ameliorating the cardiovascular complications associated with this disease [57]
(Table 4). These beneficial effects were due to the ability of the probiotic to prevent intestinal
dysbiosis occurred in experimental SLE. The administration of L. fermentum CECT5716 in
mice with SLE restored the Firmicutes/Bacteroidetes ratio and increased the levels of bacterial
species of beneficial genus such as Bifidobacterium and Parabacteroides. This restoration of
the microbiota could be responsible of the immunomodulatory activity of this probiotic
that reduced the percentage of B cells, as well as the levels of T reg (CD4+/FoxP3+)
cells, Th17 (CD4+/IL-17a+) cells, and Th1 (CD4+/IFN-γ+) cells, which were increased in
the mesenteric lymph nodes from SLE mice (Table 4). Moreover, the treatment with L.
fermentum CECT5716 significantly reduced the expression of pro-inflammatory cytokines
such as Il-17a, Ifn-γ, and Il-21 in plasma. The probiotic also ameliorated the intestinal
integrity and, together with the beneficial effects shown in the microbiota profile, resulted
in a reduction in LPS absorption in treated mice. The endothelial dysfunction that occurred
in SLE mice was reversed with the L. fermentum CECT5716 treatment, being associated
with a reduced NADPH oxidase activity and normalization of the NO production by the
endothelial nitric oxide synthase (eNOS) [57] (Table 4). The effect of L. fermentum CECT5716
on endothelial dysfunction was corroborated in previous studies, in which this probiotic
was evaluated in the tacrolimus-induced hypertension in mice [131]. The tacrolimus is
a macrolide used for maintenance of immunosuppression in organ transplant recipients
that has been shown to affect blood pressure and immunologic memory. L. fermentum
CECT5716 treatment ameliorated the hypertension induced by tacrolimus and prevented
the endothelial dysfunction occurring in this experimental group. These effects were due to
the probiotic ability of suppressing the release of endothelial-derived vasoconstrictor factors
and normalizing the expression of cyclooxygenases (Cox)-1 and Cox-2. The administration
of L. fermentum CECT5716 reduced the vascular oxidative stress by a reduction in the
activity of NADPH oxidase. It was also reported an amelioration of the immune response
preventing the altered T-cell polarization induced by tacrolimus and restoring the plasma
levels of IL-10 and IL-7. The activity demonstrated by the probiotic could be associated
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with the beneficial effects exerted on gut microbiota, which was altered by the tacrolimus
administration. In fact, L. fermentum CECT5716 restored the ratio Firmicutes/Bacteroidetes
that was increased in tacrolimus-administered mice [131] (Table 4). The preventative
effect of L. fermentum CECT5716 on the development of endothelial dysfunction and high
blood pressure in SLE genetic mice (NZBWF1) has been also evaluated, and the results
obtained revealed that L. fermentum CECT5716 protected the kidney damage and reduces
systolic blood pressure in these mice. These protective effects exerted by the probiotic were
associated with a decrease in renal oxidative stress and inflammation, derived from the
reduced plasma levels of autoantibodies and LPS [132].
All these findings support the use of L. fermentum CECT5716 in prophylaxis and/or
therapy of the complications associated with SLE. These beneficial effects are attributed to
the ability of the probiotic to modulate the gut microbiota and the immune response, reduc-
ing anti-double-stranded DNA (dsDNA) and the endotoxemia characteristic of SLE patients.
• Pregnancy and lactation.
Although these conditions are not considered as a disease, they comprise important
physiological adaptations that affect the nutritional needs, the microbiota of the mother
and, therefore the acquisition of the microbiota offspring. All of them can influence not
only the mother’s health, but the correct development and growth of the newborn. In
these periods, the immune system also undergoes alterations to achieve tolerance towards
and adequate support for the fetus and for the lactation process [133]. Pregnancy and
the increased metabolic demands during parturition and lactation result in increased
production of ROS, leading to reductions in neutrophil function, antibody responses, and
cytokine production by immune cells [134] (Table 4). Recently, an experimental model
using rats during pregnancy and lactation has demonstrated the immunomodulatory
ability of the L. fermentum CECT5716 treatment [133]. It has been shown that the treatment
with the probiotic reduces the levels of cytotoxic T cells (CD8+ TCRαβ+ and TCRγδ+) in
mesenteric lymph nodes of dams rats. Moreover, L. fermentum CECT5716 was able to
induce changes on the fatty acid profile in plasma of dams and pups rats producing an
increase in γ-linolenic acid and a reduction in total saturated fatty acids in dams [135].
These findings suggest that L. fermentum CECT5716 treatment can be a promising strategy
on pregnancy and lactation (Table 4).
Table 4. Mechanisms of action of L. fermentum CECT5716 in animal models.
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natural and acquired immune responses, as evidenced by the activation of NK and T cell 
subsets and the expansion of Treg cells, as well as induced a broad array of cytokines [83] 
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miRNA-375 expression [58] 
↓ IL-1β and NO production in stimulated cells RAW-264.7 [65] 
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The effects shown by this probiotic strain in in vitro studies have been confirmed and 
supported by different preclinical studies.  
● Animal models. 
1. Models of experimental colitis. 
These models resemble human inflammatory bowel disease (IBD). It is a medical 
term that mainly includes two different clinical states, Crohn’s disease (CD) and ulcerative 
colitis (UC), and refers to specific chronic inflammatory states in the gastrointestinal tract. 
Its etiology is complex and not fully identified, involving interaction between genes, such 
as NOD2 and ATG16L1, and a number of functional abnormalities, like imbalance be-
tween pro-inflammatory, and anti-inflammatory T cell responses [58], impaired epithelial 
barrier function and gut microbiota dysbiosis [58]. Connecting the heritability and the en-
vironmental influence, unique microRNA (miRNA) expression profile signatures have 
been associated with IBD pathogenesis. In this regard, both endogenous gut miRNAs and 
exogenous miRNAs from diet could actively modulate microbial colonization and intes-
tinal immunity [84]. Thus, gut microbiota in IBD patients differs from healthy individuals, 
as it is characterized by a reduced diversity, increased abundance of Enterobacteriaceae and 
reduced abundance of Firmicutes and Bacteroidetes phyla [85]. As well as gut microbiota is 
key for the maintenance of gut homeostasis, it could also promote chronic inflammation 
and the development of IBD [86–88] (Table 4). 
In this regard, IBD patients display a modified balance between the T helper (Th)17/T 
regulatory (Treg) and the Th1, Th2, and Treg populations [89], having been proposed that 
a downregulation of Treg together with an increase in Th17 cells participate in the loss of 
tolerance for microbiota, that triggers inflammation [90]. Additionally, since the gut mi-
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iNos, and Il-6 expression.
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crobiota produces host-beneficial substances, the changes observed in the gut microbiota 
of IBD patients are associated with decreased levels of short-chain fatty acids (SCFAs), 
protein levels.
- MPO activity. Rat [65,95]
↑ Antioxidant activity: GSH content.
Induced growth of Lactobacilli species d increased more than doubl d the
production of the SCFAs (acetate, butyrate, and propionate)
Amelioration of the weight decrease in a 20% and amelioration of diarrhea
incidence and gut dysbiosis
Mouse [27,58]↓ Tnf-
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activation and cytokine profil . The results showed hat the incubation of L. fermentum 
CECT5716 produced activation of both NK cells (CD8+ NK subset) and Treg cells 
(CD4+CD25+Foxp3+). Moreover, the probiotic was able to induce different cytokines in-
cluding Il-10, TNF ɑ, MIP-1β, IL-1β, IL-1ɑ, IL-18, and IFN-𝛾 implicated in the inflamma-
tory proc  [83]. Thus, this stud  demonstrated that L. fermentum CECT5716 enhanced 
natural a  acquired immune responses, as evidenced by the activation of NK and T cell 
subsets and the expansion of Treg cells, as well as induced a broad array of cytokines [83] 
(Table 3). 
Table 3. In vitro studies: mechanisms of action of L. fermentum CECT5716. 
Experimental Models Mechanisms of Action Cell Model Reference 
Epithelial cell lines 
↓ Expression of pro-i flammatory profile (Il-6) 
and ↑ the mucins in stimulated cells 
CMT-93 [58] 
Restoration of miRNA-150, miRNA-155, and 
miRNA-375 expression 
↓ NO, IL-8, and IL-1β in stimulated cells 
Caco-2 [65] 
↓ MAPK p42/44 ERK and p38 in stimulated cells 
Immune cells 
↓ Pro-inflammat ry mediators of stimulated cells 
(TNF-ɑ and IL-1β) and ↑ anti-inflammatory medi-
ators (IL-10) BMDM 
[71] 
Restoration of miRNA-150, miRNA-155, and 
miRNA-375 expression [58] 
↓ IL-1β and NO production in stimulated cells RAW-264.7 [65] 
Enhanced immune responses: Induction of the 
production of cytokines (TNFα, IL-1β, IL-8, MIP-
1α, MIP-1β, and GM-CSF), activation of NK and T 
cell subsets, expansion f Treg cells 
PBMC [83] 
The effe ts shown by this probiotic strain in in vitro studies have be n confirmed and 
supported by different pre linical studies. 
● Animal models. 
1. Models of experimental colitis. 
These models resemble human inflammatory bowel disease (IBD). It is a medical 
term that mainly includes two different clinical states, Crohn’s disease (CD) and ulcerative 
colitis (UC), and refers to specific chronic inflammatory states in the gastrointestinal tract. 
Its etiology is complex and not fully identified, involving interaction between genes, such 
as NOD2 and ATG16L1, and a number of functional abnormalities, like imbalance be-
tween pro-inflammatory, and anti-inflammatory T cell responses [58], impaired epithelial 
barrier function and gut microbiota dysbiosis [58]. Connecting the heritability and the en-
vironmental influence, unique microRNA (miRNA) expression profile signatures have 
been associated with IBD pathogenesis. In this regard, both endogenous gut miRNAs and 
exogenous miRNAs from diet could actively modulate microbial colonization and intes-
tinal immunity [84]. Thus, gut microbiota in IBD patients differs from healthy individuals, 
as it is characterized by a reduced diversity, increased abundance of Enterobacteriaceae and 
reduced abundance of Firmicutes and Bacteroidetes phyla [85]. As well as gut microbiota is 
key for the maintenance of gut homeostasis, it could also promote chronic inflammation 
and the development of IBD [86–88] (Table 4). 
In this regard, IBD patients display a modified balance between the T helper (Th)17/T 
regulatory (Treg) and the Th1, Th2, and Treg populations [89], having been proposed that 
a downregulation of Treg together with an increase in Th17 cells participate in the loss of 
tolerance for microbiota, that triggers inflammation [90]. Additionally, since the gut mi-
crobiota produces host-beneficial substances, the changes observed in the gut microbiota 
of IBD patients are associated with decreased levels of short-chain fatty acids (SCFAs), 
Il-1β, iNOS and Mmp-9 expression
Restoration of miR-155 and miR-223 expression
Microbiota restoration: increase microbial diversity and restore the F/B ratio.
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Table 4. Cont.
Experimental Models Mechanisms of Action Animal Model Reference
Metabolic syndrome
Prevent liver steatosis and inflammatory status
Rat [112]
↓ Glucose and insulin levels in plasma
Gut dysbiosis restoration by preventing the increase in Bacteroidetes and the
reduction in Firmicutes.
Increase the levels of Akkermansia muciniphila
Prevention of hypertriglyceridemia and hyperleptinemia
↓ Body weight gain in 15–20%
Mouse [114]
Amelioration of glucose and lipid metabolism
↑ Glut-4 expression
↓ Tnf-α and Il-1β expression and inhibition of NADPH activity in aortic tissue
Restoration of impaired endothelial disfunction
Anti-inflammatory properties: ↓ Il-6, Tnf-α, Mcp-1, and Jnk-1 expression in
liver and fat
Amelioration of obesity-associated dysbiosis:
- ↑ Richness and diversity
- Restore F/B ratio, decreasing it.
- Restore levels of Verrumicrobia,
Akkermansia and Bacteroides.
- ↑ Lactate- and acetate-producing genera.
Enhanced intestinal epithelial integrity (↑ occludin levels) and




- Restore F/B ratio.
- ↑ Bifidobacterium and Parabacteroides genera.
- ↓ Blautia and Lachnospira.
Mouse [57]
↓ Pro-inflammatory cytokine (Tnf-α and Il-1β expression) /plasma levels
of LPS
Intestinal integrity amelioration
(↑ Zo-1 and Occludin expression)
↓ Hypertension
Prevention of the endothelial dysfunction
(↑ acetylcholine-induced vasodilation)
↓ NAPDH oxidase activity
Prevention of the altered T-cell polarization
Pregnancy and
lactation stage
↓ Cytotoxic T cells
Rat [135]↑ γ-linolenic acid
↓ Saturated fatty acids
2.1.2. Human Trials
Clinical studies are crucial to really establish the potential role of probiotics in human
health and disease, thus providing evidence to support their use as a nutraceutical or
functional food. Although the preclinical studies have shown promising results, the
available clinical research focused on L. fermentum CECT5716 is scarce, and only a few
human studies have been reported. The beneficial effects of L. fermentum CECT5716
have been validated on different conditions in which an altered immune response occurs,
including mastitis and infections, mainly in infants (Table 5).
• Mastitis
Mastitis is an inflammation of breast tissue that mainly occurs during lactation, most
probably derived from an infection status, which has been associated with dysbiosis in the
breast milk microbiota. The mastitis-associated dysbiosis is characterized by an increase in
the proliferation of some bacterial species, mainly from Staphylococcus genus, together with
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the disappearance of other species, like lactobacilli or lactococci [136]. The administration
of probiotics has been proposed as a strategy to restore this dysbiotic status and alleviate
mastitis. Accordingly, and based on the immunomodulatory and anti-infectious properties
reported for L. fermentum CECT5716, this probiotic could be a therapeutic approach of
great value in this condition. In fact, different randomized double-blinded controlled trials
have reported that the consumption of L. fermentum CECT5716 (at doses ranging from
3 × 109 to 9 × 109 CFU/day) prevented lactational mastitis and/or improved some of
the inflammation-associated symptoms, including pain [137,138] (Table 5). In addition,
the levels of the chemokine IL-8, which is considered as an indicator of mastitis, was also
significantly lower in the breast milk of women treated with the probiotic. Of note, the
beneficial effects of the probiotic against mastitis were associated with an 80% reduction
in Staphylococcus counts in breastmilk, thus ameliorating the dysbiosis that characterizes
this condition [138] (Table 5). Moreover, when the effect of L. fermentum CECT5716 was
compared with a standard antibiotic treatment, those women receiving the probiotic
treatment showed an increased improvement and lower recurrence of mastitis than those
treated with the antibiotic, without showing significant differences between both treatments
when considering their beneficial impact on breastmilk microbiota composition [139]
(Table 5). Therefore, it can be concluded that the use of this strain constitutes an attractive
strategy in the management of mastitis in women, which can constitute an alternative to
the current antibiotic usage, thus providing evident additional benefits to the community
and health system.
• Viral infections
Viral infections such as influenza are a global health problem. Influenza is an acute
highly contagious viral respiratory infection caused by the influenza virus. Infected pa-
tients can show a variety of symptoms including high fever, sore throat, headache, and
running or stuffy nose, which can sometimes develop into pneumonia. At present, the
most efficient strategy to control influenza is to provide protective adaptive immunity
through the administration of a vaccine, although in some cases, the vaccine seems to
show limited clinical effectiveness [140]. To improve it, the coadministration of the in-
activated virus with adjuvants such as cholera toxin or heat-labile enterotoxin has been
used [141] and a trace amount of cholera whole toxin as an adjuvant for nasal influenza
vaccine [142,143]. However, the combination of the vaccine with these coadjuvants may
have clinical risks [144]. In this sense, it has been postulated that L. fermentum CECT5716
can act as an adjuvant therapy to vaccines in preventing these viral infections. In fact, it has
been reported that the oral administration of L. fermentum CECT5716 to adult volunteers
receiving the anti-influenza vaccine, increased the Th1 response and virus-neutralizing
antibodies, as well as increased the proportion of NK cells and the expression of TNF-α
and IL-12 after vaccination in these subjects, thus reinforcing the effect of the vaccine and
potentially enhancing systemic protection from this viral infection [140] (Table 5).
• Pediatric infections
Infectious diseases are the most common type of illness in infants worldwide. Many
studies indicate that breast-fed children have a lower incidence of infections than formula-
fed children, which could be associated with the modulation of gut microbiota by breast
milk components [145]. Indeed, many studies suggest that the gut microbial profile of
breastfed infants is dominated by Bifidobacterium [146,147], with the addition of a few
other anaerobes and small numbers of facultative anaerobic bacteria [148], whereas in
formula-fed children, the microbiota profile is different to infants fed with breast milk
at all ages, but it is most apparent at 6 months of age. Moreover, breast milk-fed infants
have a higher relative abundance of Bifidobacterium and lower abundance of bacteria of the
Clostridiaceae family [149]. In fact, breast milk influences health-promoting microorganisms
by factors such as polymeric IgA (pIgA), antibacterial peptides, and components of the
innate immune response [150]. Moreover, and compared with formulas, breast milk has
superior effects on the barrier integrity and mucosal defenses of the intestinal tract in
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children [151]. Because of its many benefits, exclusive breast-feeding for the first 6 months
of life is recommended; however, and unfortunately, breast milk feeding to children is
not always possible. It is interesting to note that although the composition of commercial
formulas is more and more close to that of breast milk, the gut microbiota of breast-fed
and formula-fed babies remains distinct [152]. For this reason, the manipulation of the
intestinal microbiota of infants through the administration of probiotics can be considered
as an interesting strategy for the prevention of community-acquired infections in children.
Thus, the impact of an infant formula supplemented with L. fermentum CECT5716 was
evaluated in a randomized controlled trial with the aim to determine the incidence rate of
gastrointestinal infection in infants aged between 1 and 6 months [153]. The results revealed
that the gastrointestinal infections were three times more frequent in infants of the control
group than in those receiving the probiotic [153] (Table 5). In another randomized double-
blinded controlled clinical trial, a formula supplemented with L. fermentum CECT5716 was
administered to infants aged 6 and 12 months in order to evaluate its effect on the incidence
of gastrointestinal and respiratory infections. The intake of the probiotic supplemented
diet significantly reduced the incidence rate of gastrointestinal infections (46%) and of
upper respiratory tract (27%) infections when compared to the corresponding control [28]
(Table 5). More recently, the incidence of infections in infants has been also evaluated in a
randomized double-blinded placebo-controlled multicenter trial in which the probiotic L.
fermentum CECT5716 was administered to the mothers for 16 weeks. Almost 300 mother–
infant pairs were included in this study. The results showed a significant lower incidence
of conjunctivitis in the infants whose mothers received the probiotic. In addition, the
group receiving the probiotic showed a lower load of Staphylococcus in the breast milk
and in infant feces, which was associated with a significantly lower risk of respiratory
and gastrointestinal infections. Therefore, this study showed that the treatment with this
probiotic might neutralize the negative effect of the Staphylococcus load on respiratory and
gastrointestinal infections in infants [28].
Table 5. Clinical studies: mechanisms of action of Limosilactobacillus fermentum CECT5716.
Disease Mechanism of Action References
Mastitis
Prevention of lactational mastitis symptoms
[143,144]↓ IL-8 levels
↓ Staphylococcus load in the breast milk
Pediatric infections
↓ Incidence of gastrointestinal and
respiratory infection [28,153]
↓ Incidence of conjunctivitis
and the load of Staphylococcus [28]
Vaccination stage ↑ Th1, NK cells, and Tnf-α and Il-12 expression [145]
3. Concluding Remarks
The different preclinical and clinical studies performed with Limosilactobacillus fermen-
tum CECT5716 have evidenced its anti-inflammatory and immunomodulatory properties
and elucidated the precise mechanisms of action involved in its beneficial effects. This
would justify its potential as a nutritional supplement in different inflammatory-related
conditions, both for treatment and prevention. Of note, the properties reported for this
probiotic cannot be generalized to other microorganisms, neither from the same genus nor
from other strains of the same species. However, and despite the promising prospect of
L. fermentum CECT5716, corroborative studies are needed for further understanding the
role of this probiotic in the modulation of gut microbial populations, which seems a key
mechanism associated with its immunomodulatory and anti-inflammatory effects both in
healthy and disease.
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